key: cord-0801061-ce0fs3fz
authors: Wang, Ling; Zhao, Juan; Nguyen, Lam N. T.; Adkins, James L.; Schank, Madison; Khanal, Sushant; Nguyen, Lam N.; Dang, Xindi; Cao, Dechao; Thakuri, Bal Krishna Chand; Lu, Zeyuan; Zhang, Jinyu; Zhang, Yi; Wu, Xiao Y.; El Gazzar, Mohamed; Ning, Shunbin; Moorman, Jonathan P.; Yao, Zhi Q.
title: Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma
date: 2021-03-10
journal: Sci Rep
DOI: 10.1038/s41598-021-84840-3
sha: af1e13ac34547f0ef5a1aa063b6743ee0a52e05b
doc_id: 801061
cord_uid: ce0fs3fz

The recent COVID-19 pandemic poses a serious threat to global public health, thus there is an urgent need to define the molecular mechanisms involved in SARS-CoV-2 spike (S) protein-mediated virus entry that is essential for preventing and/or treating this emerging infectious disease. In this study, we examined the blocking activity of human COVID-19 convalescent plasma by cell–cell fusion assays using SARS-CoV-2-S-transfected 293 T as effector cells and ACE2-expressing 293 T as target cells. We demonstrate that the SARS-CoV-2 S protein exhibits a very high capacity for membrane fusion and is efficient in mediating virus fusion and entry into target cells. Importantly, we find that COVID-19 convalescent plasma with high titers of IgG neutralizing antibodies can block cell–cell fusion and virus entry by interfering with the SARS-CoV-2-S/ACE2 or SARS-CoV-S/ACE2 interactions. These findings suggest that COVID-19 convalescent plasma may not only inhibit SARS-CoV-2-S but also cross-neutralize SARS-CoV-S-mediated membrane fusion and virus entry, supporting its potential as a preventive and/or therapeutic agent against SARS-CoV-2 as well as other SARS-CoV infections.

Severe Acute Respiratory Syndrome (SARS) triggered the first global alert for coronavirus (CoV) infections in 2003 1, 2 . Almost ten years later, a new CoV infection termed the Middle East Respiratory Syndrome (MERS) caused global outbreaks in 2012 3, 4 . In late 2019, another novel CoV (SARS-CoV-2) was identified as the causative agent of a global pandemic of viral pneumonia, named by the World Health Organization (WHO) as novel coronavirus infectious disease-2019 (COVID- 19) 5 . Although the mortality rate due to COVID-19 is relatively lower, the number of deaths has already surpassed those of SARS and MERS combined, owing to the extremely high transmissibility of SARS-CoV-2 [6] [7] [8] [9] . As of November 20, 2020, there have been 56,623,643 confirmed cases of COVID-19 and 1,355,963 deaths reported worldwide by the WHO with 11,413,788 confirmed cases and 248,571 deaths in the United States alone 5 . This pandemic nearly shutdown social and economic activities and poses a serious threat to global public health, calling for prompt development of anti-COVID-19 therapeutics and prophylactics for treatment and prevention of future outbreaks.

To combat the COVID-19 pandemic, there is an urgent need to define the molecular mechanism involved in SARS-CoV-2 spike (S) protein-mediated cell-cell fusion that is essential for the virus entry. Notably, SARS-CoV and SARS-CoV-2 share 90% sequence identity in their S protein S2 subunits (fusion domain, FD) that mediate membrane fusion, and their S1 subunits bind to the human angiotensin-converting enzyme 2 (hACE2) receptor to infect human cells 7, 8 . Importantly, recent biophysical and structural studies have shown that the ACE2-binding affinity of the receptor-binding domain (RBD, with 74% homology between the two viruses) in the S1 subunit of SARS-CoV-2 is at least fourfold higher than that of SARS-CoV 9,10 , indicating higher infectivity and transmissibility of SARS-CoV-2. Also, recent cell-cell fusion assays have shown that SARS-CoV-2 S protein is much more www.nature.com/scientificreports/ in the COVID-19 convalescent plasma was quantitated using a high-sensitive SARS-CoV-2 S1 IgG ELISA kit (BioVendor, Asheville, NC). www.nature.com/scientificreports/ equal variances. The magnitude of correlation was analyzed with Pearson's correlation coefficient (parametric approach). P-values of < 0.05 were considered statistically significant.

ize COVID-19 humoral immune responses, we collected blood samples from COVID-19-recovered subjects and assayed for the presence of specific IgM and IgG antibodies in plasma (1:100 diluted) by ELISA Kits, which use SARS-CoV-2-S1 RBD as a capture antigen. As shown in Fig. 1a , all tested subjects were negative for anti-RBD IgM antibody, including COVID-19-recovered subjects and control individuals. Amongst the eleven COVID-19 subjects studied, six (S2, S3, S4, S5, S6, and S11) remained positive for anti-RBD IgG antibody, three (S1, S8, and S9) were marginally positive or cutoff (OD 450: 0.2), and two (S7-119 days after diagnosis and S10-32 days after diagnosis) were IgG negative (Fig. 1b) . All control subjects, including eight healthy subjects (H), four Influenza subjects (F), and one HIV subject (HIV), were tested negative for the SARS-CoV-2 S1 RBD IgG antibody. These results suggest that SARS-CoV-2 S1 RBD IgG antibodies in the plasma of some COVID-19 patients are maintained at very low levels or diminished quickly after recovery. To ensure virus-specific antibodies against other epitopes on the SARS-CoV-2 S1 subunit, which contains N-term domain (NTB) and RBD, a high-sensitive SARS-CoV-2 S1 IgG ELISA kit (BioVendor, Asheville, NC) was used for the quantitative detection of anti-S1 IgG titers in the patient's plasma. Notably, the titers of anti-S1 IgG antibody (Table 1) were found compatible with the OD450 values of anti-RBD IgG antibody (Fig. 1b) .

To measure protective NAbs, COVID-19 convalescent plasma was diluted (1:10) and incubated with HRPconjugated, recombinant SARS-CoV-2-S1 RBD for 30 min at 37 °C prior to adding to an ACE2 pre-coated ELISA plates. The inhibition extents of S and ACE2 interactions were calculated as described in the Materials and Methods. As shown in Fig. 1c and Table 1 , seven of the COVID-19 subjects (S2, S3, S4, S5, S6, S11 and S23) exhibited inhibition extents greater than 80-90%; five COVID-19 subjects (S1, S8, S9, S10 and S30) showed 30-70% inhibition extents; two COVID-19 subjects (S7 and S21) showed inhibition extents lower than the 20% cutoff which suggesting no detectable SARS-CoV-2-S1 RBD NAbs. All negative controls (four Influenza patients and two healthy subjects) showed undetectable NAbs to SARS-CoV-2-S1 RBD. Importantly, the inhibition extents positively correlated with the levels of SARS-CoV-2-S1 anti-RBD IgG antibodies (r = 0.8737, p = 0.0004) (Fig. 1d) as well as the anti-S1 IgG antibodies (r = 0.8457, p = 0.0005) in these COVID-19 patients (Fig. 1e) , analyzed by the Pearson Correlation. These results indicate that most of the COVID-19-recovered patients have high titers of NAbs to SARS-CoV-2-S1 as well as RBD epitopes in their convalescent plasma.

an RBD in S1 and an FD in S2 working in synergy to bind to the ACE2 receptor on target cells and induce cell membrane fusion for viral entry 11, 12, 25 . To establish an assay for measuring SARS-CoV-2-S-mediated cell-cell fusion, we employed 293 T cells expressing both SARS-CoV-2-S and enhanced green fluorescent protein (EGFP) as effector cells and 293 T cells stably expressing the human ACE2 receptor (ACE2/293 T) as target cells. Figure S1a shows the results of the restriction enzyme digestion of the pCDNA3.1/SARS-CoV-2-S and pCDNA3.1/SARS-CoV-S plasmids used for cell transfection, both of which contain the S gene. Figure 2a shows similar expression levels of SARS-CoV S and SARS-CoV-2 S protein in the plasmid-transfected effector cells. Western blot analysis showed that the stably transfected ACE2/293 T cells expressed the Myc-ACE2 protein (Fig. 2b) , and immunofluorescence assays showed cell surface expression of the S protein in pCDNA3.1/SARS-CoV-2-S transfected 293 T cells (Fig. S1b) . Notably, when the effector cells and the target cells were co-cultured at 37ºC for 4 h and 24 h, the two types of cells started to fuse at 4 h and the fused cells exhibited a much larger size and multiple nuclei compared to the unfused cells. These changes were more significant at 24 h, resulting in hundreds of cells fused as one large syncytium with multiple nuclei that could be easily seen under both light and fluorescence microscopy (Fig. 2c) , which is similar with syncytium formation induced by SARS-CoV-2 infection 11, 26 . Also, the fluorescence intensity in the fused cells became weaker as a result of EGFP diffusion from the effector cells to multiple target cells. The cell fusions were observed in both SARS-CoV and SARS-CoV-2 groups, whereas those cells transfected with EGFP only without the S protein did not elicit such an effect, confirming that CoV S-ACE2 engagement is essential for viral fusion and entry. Consistent with a previous study showing that SARS-CoV-2 S protein binds to ACE2 with a higher affinity than SARS-CoV S protein 9 , our results showed that the SARS-CoV-2 group exhibited a greater number and larger size of fused cells compared to the SARS-CoV group (Figs. 2c and 3) . These results support the notion that SARS-CoV-2 S has a higher ACE2 binding affinity (related to S1 RBD) and/or fusion capacity (related to S2 FD) that mediates viral fusion and entry into the target cells compared to SARS-CoV S 25 .

To determine whether the plasma of COVID-19 patients can block S protein-mediated cell-cell fusion, we incubated the effector cells with COVID-19 convalescent plasma with different titers of NAbs (S2, S3, S21, S23 and S30) at 37 °C for 30 min and then washed the cells prior to co-culturing with the ACE2/293 T target cells. This step allows the S protein expressed on the effector cells to sufficiently bind to the S protein-recognizing antibodies present in the plasma. We first performed cell-cell fusion assays using 80 ng/ml of Trypsin-DMEM, which facilitates plasma membrane fusion 11, 12, 25 . We found that cell fusion occurred in both SARS-CoV-S and SARS-CoV-2-S groups compared to non-S, EGFP-transfected cells at 4 h after the effector cells were overlaid on top of the target cells under this condition. However, not only fewer fusing cells were observed, but also the sizes of fused cells were much smaller in the groups of SARS-CoV-2-S/293 T effector cells pre-incubated with 10% or 20% convalescent plasma from COVID-19 patients compared to that without patient plasma pre-incubation (Fig. 3a, upper panel) . www.nature.com/scientificreports/ We also employed a culture condition with 10% fetal bovine plasma (FBS, without trypsin)-DMEM for cell-cell fusion assays and obtained the same results (Fig. 3a, lower panel) , except that trypsin appeared to be essential for SARS-CoV-S-mediated membrane fusion (at least at the early, 4 h incubation phase), whereas SARS-CoV-2 did not require exogenous trypsin for efficient cell fusion (compare to Fig. 3a, upper panel) . Counting of fused cells per field in at least four randomly selected fields revealed a remarkably higher number of cell-cell fusions in the SARS-CoV-2 group than the SARS-CoV group, and the SARS-CoV-2 S-mediated cell-cell fusions were significantly reduced by convalescent plasma with high titers of NAbs (S2, S3, S23 and S30), but not by S21 convalescent plasma with undetectable NAbs (Figs. 3c and S2a). Further Pearson Correlation analysis showed that the numbers of fusing cells per field negatively correlated with inhibition extents of S/ACE2 interaction (Fig. 3d) , indicating that the efficiency of blocking cell-cell fusions is closely associated with the convalescent plasma NAb titers. As negative controls, plasma from Influenza-2 patient or HS-19 was also tested using the same approach, but did not elicit significant inhibition on cell-cell fusion mediated by the SARS-CoV-2 S-ACE2 interactions (Figs. 2a, 3b , and c). Western blots were performed using whole cell lysates from the cell-cell fusion samples with anti-SARS-CoV-2 S Protein (RBD) antibody, which recognizes the full-length S protein and cleaved S1 protein. Notably, the cleaved S1 bands were much weaker compared to full-length S bands, and there were no significant differences in S1 protein levels among different samples (Fig. S2b) . Taken together, these results demonstrate that SARS-CoV-2-S protein could effectively mediate cell-cell fusion in the absence of an exogenous proteolytic enzyme (e.g., trypsin), and the COVID-19 convalescent plasma could neutralize SARS-CoV-2 S-mediated membrane fusion and virus entry.

pSARS-CoV-2-S Δ19 plasmid expresses a SARS-CoV-2 S mutant, which is truncated 19 amino acids from the C-terminus to improve the assembly of lentivirus expressing S protein. Based on a previous study, PsV made with truncated S protein generates about tenfold higher titers of infectious particles than those made with a full-length SARS-CoV-2 S protein 24 . Thus, this PsV expressing SARS-CoV-2-S Δ19 plasmid was used for our neutralization assays.

Since the PsV carried both luciferase and EGFP genes, the fluorescent images were captured before performing the luciferase assays, and representative EGFP images are shown in Fig. 4a . Notably, using convalescent plasma from COVID-19-recovered subjects with high (S2), medium (S9), and low IgG/NAb antibodies (Fig. 1b  and c) , we observed more EGFP + cells in samples with more dilution and/or with lower IgG level (Fig. 4a) , which indicates that PsV infection inhibitory capacity was reduced by the dilution and lower IgG level of convalescent plasma. Our neutralization assays showed that all six patients' plasma exhibited a concentration-dependent inhibition of SARS-CoV-2 S PsV infection. S7 plasma (with the lowest IgG/NAb level) showed the weakest inhibition of viral infection, whereas S2, S4 and S11 plasma (with relatively higher IgG/NAb levels) showed a relatively stronger inhibition than other patient plasma (Fig. 4b) . These results are consistent with the titers of The IgM and IgG antibodies against SARS-CoV-2-S1 RBD were detected in the plasma of COVID-19-recovered subjects and control subjects by ELISA. (c) The NAbs that block the interactions of SARS-CoV-2-S1 RBD and hACE2 were determined by an ELISA Test kit. (d-e) The correlation between the inhibition extent of NAbs and OD450 values of anti-S1 RBD as well as anti-S1 IgG antibodies. All the graphs in 1 were created by Prism 6.01 software (https ://www.graph pad.com/). www.nature.com/scientificreports/ S1 IgG neutralizing antibodies ( Table 1 ), suggesting that a higher titer of IgG NAbs has a stronger inhibition for SARS-CoV-2 infection. According to Fig. 4b , the plasma dilution factors and the amounts of S1 IgG antibodies in the plasma were considered and a calculation was made on the basis that 1.51-7.16 ng/ml of S1 IgG antibodies resulted in a 50% reduction in SARS-CoV-2 infection (Fig. 4c ).

Despite the poorly defined pathogenesis of COVID-19, the majority of SARS-CoV-2-infected individuals spontaneously recover, suggesting that host immunity is naturally induced in COVID-19-recovered subjects. An explicit study of COVID-19, particularly of host immunity to this viral infection in recovered subjects, will lay a foundation for a rational design of therapeutics and/or vaccines against future outbreaks. In this study, we examined the SARS-CoV-2 specific IgM and IgG antibodies, and found that IgM antibodies against the S protein RBD domain were negative for all COVID-19 subjects, even for one subject (S11) whose blood was collected 17 days after the onset of symptoms. These results suggest that the IgM antibody against SARS-CoV-2-S1 RBD diminishes quite early, or that it may never achieve a seroconversion for IgM antibody, against the RBD epitope during viral infection. Amongst the 11 COVID-19 subjects tested for IgG antibodies, 6 subjects remained positive, 3 subjects were borderline, and 2 were negative. These results indicate that SARS-CoV-2 RBD-specific antibodies may wane quickly after recovery in some patients and are not reliable for assessing humoral immune responses or herd immunity. Virus neutralization is the reduction of virus infectivity by an antibody 27 www.nature.com/scientificreports/ virions and target cells. Moreover, NAbs can inhibit viral entrance to the target cells at different stages, such as coreceptor engagement, endocytosis, membrane fusion, or viral penetration 28 .

As the primary target for NAbs, the RBD of SARS-CoV-2 S1 subunit is a major focus for the development of NAbs against SARS-CoV-2. Many NAbs targeting the RBD have been shown to inhibit the association between the S protein and ACE2 [29] [30] [31] [32] [33] [34] [35] [36] . Sequence comparisons of MERS-CoV strains have shown that the RBD of the S protein has very high natural mutation rate, indicating that individually applied RBD-targeting antibodies might induce resistance mutations in the virus 37 . Some antibodies targeting the N-terminal domain (NTD) of the SARS-CoV-2 S1 subunit exhibit high neutralization potency to SARS-CoV-2 38, 39 . The heptad repeat loops (HR1 and HR2) of the S2 subunit, required for membrane fusion, might be another good target. The NAbs that target the S2 subunit have rarely been reported. The 1A9 antibody is the only known monoclonal antibody that binds the HR2 domain on S2 subunit of SARS-CoV, and it can block HR1-HR2 interaction and thus inhibit S2-mediated membrane fusion 40 . S21P2 is a SARS-CoV-2 peptide that covers part of the fusion peptide (FP) of S2 subunit. One study has reported that sera depleted of antibodies that target peptide S21P2 can significantly reduce the ability to neutralize SARS-CoV-2 pseudovirus infection compared with the non-depleted sera control 41 .

Interaction between SARS-CoV-2 S protein with the cellular receptor is the first step for viral entry and infection. Specifically, after the RBD in the S1 subunit of SARS-CoV-2 S protein on the virion binds to the ACE2 receptor on target cells, the FDs in the S2 subunit of the S protein undergo conformational changes and interact with each other, thus bringing the viral and cellular membranes into close proximity and allowing for the fusion peptide be inserted into the host target cell membrane for fusion, thus facilitating viral infection as well as transmission 42 . In this study, we demonstrate that SARS-CoV-2 has a greater capacity to induce cell-cell fusion than SARS-CoV. Coronavirus entry into target cells can be achieved via two routes: early plasma membrane pathway and late endosome pathway 43 . It has been reported that protease cleavage is required for activation of the fusion potential of CoV-S proteins [44] [45] [46] and that the availability of these proteases, including furin, trypsin, cathepsins, transmembrane protease serine protease-2 (TMPRSS2), and human airway trypsin-like protease on the target cells determines whether CoVs enter the cells through the plasma membrane or endocytosis [47] [48] [49] [50] [51] [52] [53] [54] . www.nature.com/scientificreports/ In the absence of exogenous or membrane-bound proteases, coronavirus can be internalized via the endosome pathway 55, 56 . In this study, we discovered that SARS-CoV-2 can efficiently induce cell-cell fusion without the need to an exogenous proteolytic enzyme (e.g., trypsin), suggesting that SARS-CoV-2 may utilize the plasma membrane fusion pathway to enter the host cells. Previous studies showed that TMPRSS2 (a serine protease) plays an important role in the cleavage and activation of SARS-CoV S protein that is required for membrane fusion and host cell entry [57] [58] [59] . In addition, recent studies have demonstrated that SARS-CoV-2 also utilizes TMPRSS2 for SARS-CoV-2 S protein priming and S protein-driven cell entry into human lung epithelium and small intestinal enterocytes 60, 61 . TMPRSS2 may also thwart the antiviral effect of Interferon-induced transmembrane proteins (IFITMs) that block virus entry by inhibiting S protein-mediated fusion 26 . Notably, Camostat mesylate, a clinically approved TMPRSS2 inhibitor, partially blocked SARS-CoV-2 S protein-driven entry into target cells. Complete inhibition of TMPRSS2 was achieved by the simultaneous use of camostat mesylate and E-64d (an inhibitor of cathepsin B/L), indicating that both TMPRSS2 and cathepsin B/L can be used for SARS-CoV-2 S protein priming 60 . Thus, the research to develop specific inhibitors for SARS-CoV-2 S may reveal potential targets for blocking the viral life-cycle and infection or transmission. Recently, the FDA has approved convalescent plasma as a potential treatment for COVID-19 62 . Our findings support this approval by the evidence that the COVID-19 convalescent plasma could recognize and bind to the SARS-CoV-2 S protein expressed on the effector cells, resulting in inhibition of S protein binding to the ACE2 receptor on the target cells and thus blockade of cell-cell fusion. Also, we observed cross-reactivity between SARS-CoV-2 plasma and SARS-CoV, suggesting that COVID-19 convalescent plasma may not only neutralize SARS-CoV-2 S-mediated but also SARS-CoV S-mediated membrane fusion and virus entry. Other clinical parameters, such as the time of convalescent plasma delivery following viral infection, the concentration of neutralizing antibody within the donated convalescent plasma, and the presence or absence of an existing host humoral immune response, may complicate the interpretation of clinical trial data. However, our study presents the potential paradigm for using COVID-19 convalescent plasma as a preventive and therapeutic agent against SARS-CoV-2 infection.

The datasets generated and analyzed during the course of this study are available from the corresponding author upon reasonable request. The data sharing policies will be followed per NIH and VA guidelines. 

A novel coronavirus associated with severe acute respiratory syndrome

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

MERS in South Korea and China: a potential outbreak threat?

Coronavirus disease (COVID-2019) situation reports

Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Antibody response to SARS-CoV-2 infection in humans: a systematic review

Kinetics of viral load and antibody response in relation to COVID-19 severity

Treatment with convalescent plasma for influenza A (H5N1) infection

Evaluation of convalescent plasma for ebola virus disease in guinea

Treatment of severe acute respiratory syndrome with convalescent plasma

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection

The convalescent sera option for containing COVID-19

Neutralizing antibody response in mild COVID-19

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensinconverting enzyme 2

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Syncytia formation by SARS-CoV-2-infected cells

Viral Immunology and Immunopathology

Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives

A human monoclonal antibody blocking SARS-CoV-2 infection

Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain

Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium

Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease

The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies

Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2

Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2

Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism

Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry

Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Emergency use authorization declaration

/scientificreports/ Reprints and permissions information is available at www.nature.com/reprints

The authors thank Dr. Hyeryun Choe (The Scripps Research Institute, Jupiter, Florida) for generously providing the ACE2/293T cells, and Dr. Paul D. Bieniasz (The Rockefeller University, New York, NY) for kindly providing the pseudovirus related plasmids. This publication is the result of work supported with resources and the use of facilities at the James H. Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.

This work was supported by an American Diabetes Association award 7-20-COVID-149; and in part by National Institutes of Health grants R01AI114748, R21AI138598, and S10OD021572; VA Merit Review Awards 1I01BX002670 and 1I01BX004281; and DoD Award PR170067 (to Z.Q.Y).

The authors declare no competing interests.

The online version contains supplementary material available at https ://doi. org/10.1038/s4159 8-021-84840 -3.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.